DeepNewz Markets

Regeneron Invests $100M in Mammoth for CRISPR-Based Gene Editing Therapies

Apr 25, 2024, 11:30 AM

Regeneron Pharmaceuticals has announced a significant expansion into gene editing by partnering with Mammoth Biosciences. The collaboration aims to research, develop, and commercialize CRISPR-based gene editing therapies for various diseases, targeting multiple tissues and cell types. Regeneron will make a substantial financial commitment, including a $5 million upfront payment and a $95 million equity investment in the CRISPR startup, totaling $100 million. This move is part of Regeneron's broader strategy to deepen its capabilities in genetic medicines, including a recent acquisition in cell therapy and ongoing partnerships focused on developing treatments for rare diseases like transthyretin amyloidosis. Mammoth, which previously developed CRISPR technology for COVID-19 diagnostics, has shifted focus to smaller DNA-cutting enzymes that could be more easily delivered into tissues across the body.

View original story

Markets

FDA Approval for Regeneron-Mammoth CRISPR Therapy by 2028?

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

Yes • 50%

No • 50%

FDA announcements, Regeneron or Mammoth press releases

First CRISPR Therapy Development by 2025

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

No • 50%

Yes • 50%

Press releases or official statements from Regeneron or Mammoth Biosciences

First gene therapy product announced by Regeneron and Mammoth by 2026?

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

No • 50%

Yes • 50%

Official press release from Regeneron or Mammoth Biosciences

New Gene Editing Enzyme Patent by 2024

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

Yes • 50%

No • 50%

US Patent and Trademark Office records or company announcements

Regeneron and Mammoth partnership terminated by 2027?

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

Yes • 50%

No • 50%

Official press release from Regeneron or Mammoth Biosciences

Regeneron Increases Investment in Mammoth by 2026?

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

Yes • 50%

No • 50%

SEC filings, financial news outlets

Regeneron-Mammoth CRISPR Therapy Clinical Trials by 2025?

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

No • 50%

Yes • 50%

Regeneron or Mammoth Biosciences press releases, SEC filings

Regeneron stock price increases by over 15% within one year due to Mammoth investment?

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

No • 50%

Yes • 50%

Stock market data and financial news outlets

Regeneron Ups Investment in Mammoth by 2025

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

Yes • 50%

No • 50%

Financial disclosures or press releases from Regeneron or Mammoth Biosciences

Financial status of Mammoth Biosciences one year after Regeneron's investment

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

Profitable • 25%

Break-even • 25%

Minor losses • 25%

Significant losses • 25%

Financial statements, press releases, or major financial news outlets

First Commercial Region for Regeneron-Mammoth CRISPR Therapy

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

Asia • 25%

Global (Simultaneous Multi-Region) • 25%

North America • 25%

Europe • 25%

Market launch announcements, healthcare regulatory bodies

First CRISPR-Based Product Type from Regeneron-Mammoth

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

In Vivo Therapy • 33%

Ex Vivo Therapy • 33%

Diagnostic Tool • 34%

Product announcements, Regeneron or Mammoth press releases

First Disease Target for CRISPR Therapy

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

Other • 20%

Cancer • 20%

Rare genetic disorders • 20%

Heart disease • 20%

Neurological disorders • 20%

Clinical trial registries or official announcements from Regeneron and Mammoth Biosciences

First Disease Target for Regeneron-Mammoth CRISPR Trials

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

Rare Genetic Disorders • 25%

Cancer • 25%

Neurodegenerative Diseases • 25%

Heart Disease • 25%

Clinical trial registries, Regeneron or Mammoth press releases

First type of disease targeted by Regeneron and Mammoth partnership

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

Cardiovascular diseases • 25%

Cancer • 25%

Neurodegenerative diseases • 25%

Rare genetic disorders • 25%

Research publications or official announcements from Regeneron or Mammoth Biosciences

Number of CRISPR Therapies by 2026

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

3 or more • 25%

0 • 25%

1 • 25%

2 • 25%

Company press releases, official statements, or annual reports from Regeneron and Mammoth Biosciences

Significant gene editing research milestone achieved by Regeneron and Mammoth in the first year

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

Successful editing of a complex genetic condition in vitro • 33%

Discovery of a new CRISPR enzyme • 33%

Patenting a novel delivery mechanism • 34%

Scientific journals or official press releases from either company

Success Rate of Initial CRISPR Clinical Trials by 2027

Regeneron Pharmaceuticals•Mammoth Biosciences•Regeneron•Mammoth

Resolution / Starting Odds

25% to 50% • 25%

Above 75% • 25%

51% to 75% • 25%

Below 25% • 25%

Clinical trial results published in medical journals or press releases from Regeneron and Mammoth Biosciences

Looking for markets...